ABSI
Absci Corp

3,027
Mkt Cap
$446.82M
Volume
2.27M
52W High
$5.23
52W Low
$2.01
PE Ratio
-3.45
ABSI Fundamentals
Price
$2.94
Prev Close
$2.92
Open
$2.86
50D MA
$2.79
Beta
2.41
Avg. Volume
2.84M
EPS (Annual)
-$0.8421
P/B
2.34
Rev/Employee
$20,000.00
$338.36
Loading...
Loading...
Poll

Earnings Recap

• Reported GAAP EPS of -$0.20 up 20.00% YoY • Reported revenue of $0.65M down -2.26% YoY • Absci expects interim proof-of-concept data for ABS-201 in androgenetic alopecia in the second half of 2026, and plans to initiate a Phase 2 clinical trial for ABS-201 in endometriosis in Q4 2026.

Bullish

Absci utilizes its AI-native platform for capital-efficient drug development, focusing on unmet medical needs. Early ABS-201 clinical data shows a favorable safety profile, with preclinical studies indicating significant hair regrowth.

Bearish

Absci faces increasing net losses and R&D expenses, requiring more capital. Biologic drug development is uncertain and competitive, with regulatory changes and AI technology risks potentially delaying programs.

Latest ABSI News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.